Personalizing Progress: New Data Shaping Care in Central Precocious Puberty

Panelists discuss how central precocious puberty involves early activation of the hypothalamic-pituitary-gonadal axis before age 8 in girls and age 9 in boys, requiring individualized treatment decisions based on factors like growth velocity, bone age advancement, and psychosocial impact, with GnRH agonist therapies available in multiple formulations (injections and implants) that effectively suppress puberty while preserving final height potential and having reassuring long-term safety profiles for bone health and fertility outcomes.